#ESC22 in Barcelona (Credit: Endpoints Associate Editor Kyle LaHucik)
August 29, 2022 07:27 AM EDTUpdated 01:34 PM
R&D
Pharma

#ESC22: Bay­er's chron­ic kid­ney dis­ease drug miss­es the mark on low­er­ing car­dio­vas­cu­lar death

Kyle LaHucik

Senior Reporter

BARCELONA — It’s been a rough two days for Bay­er at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy Con­gress. Just af­ter re­port­ing dis­ap­point­ing re­sults for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times